Valiant Laboratories Ltd IPO: Issue Details, Open/Close Date | Research 360 by Motilal Oswal
Back arrow

Valiant Laborato

CMP

148.65

-0.05 (-0.03%)

₹140

Offer Price

₹ 152.46 Cr

Issue Size

₹ 14,700

Min Investment

29.76x

Times Subscribed

105

Lot size

Time Line

  • 27
    Sep 2023
    Open
  • 03
    Oct 2023
    Close
  • 04
    Oct 2023
    Finalisation of Basis of Allotment
  • 05
    Oct 2023
    Initiation of Refunds
  • 05
    Oct 2023
    Transfer of Shares to Demat Account
  • 06
    Oct 2023
    Listing Date

Shares Offered

Number of Times Subscribed

Objects of the Offer

  • Diversification into new chemistries and industry.

  • Increase in market share.

  • Improve operational efficiencies through backward integration of Proposed Facility:

  • Increase its penetration into international markets including regulated markets.

Products & Services

  • The Company is an Active Pharmaceutical Ingredient ("API") / Bulk Drug manufacturing company

Strengths

  • Experienced promoter and strong management team:

  • Strong Focus on Sustainability in Operations:

  • Strategically located manufacturing facility:

  • Quality-Focused Compliant Manufacturing and R&D Infrastructure:

  • Reducing dependence on import of raw materials:

Risks

  • The company is subject to strict quality requirements, regular inspections and audits by its customers and any failure to comply with quality standards may lead to cancellation of existing and future orders and could negatively impact the company business, financial condition, results of operations and prospects it may impact the reputation as well.

  • The company does not have long-term agreements with its suppliers for raw materials and an inability to procure the desired quality, quantity of its raw materials in a timely manner and at reasonable costs, or at all, may have a negative impact on the business, results of operations, financial condition and cash flows.

  • If there are delays in setting up the Proposed Facility or if the costs of setting up and the possible time or cost overruns related to the Proposed Facility or the purchase of plant and machinery for the Proposed Facility are higher than expected, it could have a material adverse effect on its financial condition, results of operations and growth prospects.

  • The company`s single product manufacturing company and any changes to the paracetamol API industry or the company product demand will adversely affect its revenues, financials and profitability.

  • The majority of its operative income is derived from the domestic market and any adverse developments in this market could adversely affect its business.

Company Promoters

Promoters Holding

Issue For IPO
20.68%
Pre Holding

82.52%

Post Holding

61.84%

Top Promoters Holding

Financials

All values in Cr

Mar-2023 Mar-2023 Mar-2023 3-Yr trend
Revenue 29.00 (-) 333.91 (-) 28.90 (-)
Gross Profit 29.00 (-) 333.91 (-) 28.90 (-)
Net Income 29.00 (-) 333.91 (-) 28.90 (-)
Assets 29.00 (-) 333.91 (-) 28.90 (-)
Liabilities 29.00 (-) 333.91 (-) 28.90 (-)

Peers

Company Name Revenue (Cr) Net Profit (Cr) Assets (Cr) Liabilities (Cr) ROE EPS BVPS Current Ratio Debt to Assets
Valiant Laboratories Ltd 333.91 29.00 161.75 61.26 28.90 0.00 30.86 2.88 0.37
Granules India Ltd 4,511.92 516.60 4,904.56 4,904.56 18.22 21.00 117.13 10.53 0.37
Jagsonpal Pharmaceuticals Ltd 236.71 26.72 194.95 194.95 16.81 10.20 60.65 13.70 0.00
Alkyl Amines Chemicals Ltd 1,682.34 228.66 1,590.09 1,590.09 19.56 44.75 228.58 14.38 0.07
Laxmi Organic Industries Ltd 2,796.64 124.57 2,412.20 2,412.20 8.82 4.67 53.26 5.16 0.28

Book Running Managers

  • Unistone Capital Pvt Ltd

Registrar & Transfer Agent

Link Intime India Pvt Ltd

C-101 247 Park,
L B S Marg,
Vikhroli West - Mumbai-400083
Phone : 91-22-49186000 Fax: 91-22-49186060

Company Contact Information

104 Udyog Kshetra Mulund,
Goregaon Link Rd Mulund West,
Mumbai - 400080
Phone : +91 22 49712001 Email : complianceofficer@valiantlabs.in www.valiantlabs.in

Offer Related Information

Initial public offer of up to 10,890,000 equity shares of face value of Rs. 10 each ("Equity Shares") of Valiant Laboratories Limited ("Company" or "Issuer") for cash at a price of Rs. 140 per equity share (including a share premium of Rs. 130 per equity share) ("Issue Price") aggregating up to Rs. 152.46 crores ("Issue"). The issue shall constitutes 25.06% of the fully-diluted post- issue paid-up equity share capital of the company. The face value of equity shares is Rs. 10 each. The... More

News

  • No Data Found.

Take your research to the next level.
Login now to unlock Exclusive Features!

Download Our App On: